SCHEMBL13221272

SCHEMBL13221272

Cc1cc(Nc2nc(Sc3cccc(C(N)=O)c3)cc3nccn23)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K2 Q12851 5/20 0.40
▸ AURKB Q96GD4 9/20 0.39
▸ AURKA O14965 8/20 0.39
▸ GSK3B P49841 3/20 0.37
▸ SYK P43405 4/20 0.37
▸ SRC P12931 2/20 0.37
▸ MAP4K4 O95819 2/20 0.37
▸ PKN2 Q16513 2/20 0.37
▸ SLK Q9H2G2 2/20 0.37
▸ KDR P35968 2/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ INSR P06213 1/20 0.37
▸ LCK P06239 1/20 0.37
▸ LYN P07948 1/20 0.37
▸ RET P07949 1/20 0.37
▸ ROS1 P08922 1/20 0.37
▸ FER P16591 1/20 0.37
▸ BLK P51451 1/20 0.37
▸ RPS6KA3 P51812 1/20 0.37
▸ PRKCD Q05655 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13221268 0.92 CCNA2 (0.39) AURKBAURKAGSK3BSYKSRC
SCHEMBL13221266 0.90 PTK2 (0.39) MAP4K2AURKBAURKACDK2ROCK1
SCHEMBL13221262 0.86 AURKA (0.39) MAP4K2AURKBAURKAGSK3BSRC
SCHEMBL13221275 0.84 PRKAG1 (0.36) AURKBAURKAGSK3BSRCJAK2
SCHEMBL13221270 0.83 AURKA (0.43) AURKBAURKAGSK3BSRCAURKC
SCHEMBL13221278 0.83 CDK7 (0.36) AURKBAURKAGSK3BSRCJAK2
SCHEMBL13221269 0.82 AURKA (0.42) AURKBAURKAGSK3BSRCAURKC
SCHEMBL13221279 0.81 RET (0.36) MAP4K2AURKBAURKAGSK3BSRC
SCHEMBL13220985 0.81 AURKA (0.42) AURKBAURKAGSK3BSRCAURKC
SCHEMBL13221276 0.81 RET (0.43) AURKBAURKARETBTKAURKC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216765-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 MAP4K2 16/4885AURKB 122/4885AURKA 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback